This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Investing in Life-Changing
New Medicines
Access Biotechnology by numbers
2019
established
Led by former head of worldwide clinical R&D at Pfizer, Liam Ratcliffe.
30+
investments
A portfolio of private and public biopharma investments.
5+
exits
Access has backed high-quality small biotech firms that have been acquired by large pharma.
Access Biotechnology invests in transformative therapies for conditions with high unmet needs and that have the potential to meaningfully impact human health.
Our approach is characterized by the following:
Broad Scope
We invest in both private and public biopharma companies across therapeutic areas, modalities, and development stages – from discovery-stage technology platforms to late-stage clinical programs.
Long-Term Orientation
Free from the constraints of a typical venture fund cycle, we aim to support the growth of our portfolio companies and build our investments over the long haul.
Flexibility
We adapt our approach to the needs of individual opportunities, while continually adjusting to shifts in the external environment.
Technical Rigor
We leverage our medical and scientific backgrounds to evaluate opportunities deeply, thoughtfully, and efficiently.
Collaborative Style
We partner with founders, management, and fellow investors to build and grow companies that are developing important new medicines.
Emphasis on Fundamental Value Creation
We invest in people, data, and innovation, not momentum or hype. We believe that financial returns will reflect the value we create for patients, caregivers, and society.
Access participated in Disc Medicine’s $50 million Series A in September 2019.
Disc Medicine is developing novel treatments for dysregulated iron metabolism.
Visit Disc Medicine
Climb Bio
Climb Bio is developing budoprutug, an anti-CD19 antibody designed for a broad range of B-cell mediated diseases.
Visit Climb Bio
The company was acquired by Sanofi for $3.7B in September 2020.
Principia was focused on developing novel therapies for immune mediated diseases.
Visit Principia Biopharma
Access participated in the Series A financing of Day One announced in May 2020.
Day One develops therapies for people with cancer of all ages.
Visit Day One Biopharmaceuticals
Access led Perfuse’s Series A financing in July 2020.
Perfuse is pursuing a novel mechanism to improve retinal perfusion for the treatment of multiple eye diseases.
Visit Perfuse Therapeutics
Access participated in Nimbus’ $105M private financing announced in July 2021.
Nimbus harnesses cutting-edge technologies to design exquisitely selective small molecule therapeutics.
Visit Nimbus Therapeutics
Access participated in Recludix’s $60M Series A announced in November 2021.
Recludix is discovering and developing potent and selective inhibitors for challenging protein targets in cancer and inflammatory diseases.
Visit Recludix Pharma
Access led Halda’s Series B financing in December 2021.
Halda is discovering and developing novel small molecule drugs for cancer.
Visit Halda Therapeutics
Access co-led Pandion’s $80M Series B financing in March 2020. The company was acquired by Merck for $1.85 billion in April 2021.
Pandion is developing biologic therapies for serious autoimmune disorders.
Visit Pandion Therapeutics
Access participated in Upstream’s $200M Series A financing announced in June 2022.
Upstream is developing novel therapies for inflammatory and allergic diseases.
Visit Upstream Bio
Access participated in the company’s $350 million Series A financing announced in July 2022.
Areteia is developing an oral drug for eosinophilic (allergic) asthma.
Visit Areteia Therapeutics
Access led the company’s $300M Series C financing in September 2022.
Acelyrin is focused on identifying, acquiring, and developing transformative new therapies for conditions with high unmet need in autoimmunity and other disease areas.
Visit Acelyrin
Access co-incubated the company, and co-led the Seed financing announced in October 2022.
Matchpoint is discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
Visit Matchpoint Therapeutics
Access led Hemab’s Series B in February 2023.
Hemab is developing therapies for serious inherited bleeding disorders.
Visit Hemab Therapeutics
Access participated in Zura’s $80M private placement announced in April 2023.
Zura is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
Visit Zura Bio
Access led Vyne’s $88M private placement in October 2023.
Vyne is developing novel therapies for vitiligo and other autoimmune and inflammatory disorders.
Visit Vyne Therapeutics
Apogee Therapeutics
Apogee Therapeutics is developing novel biologic therapies for inflammatory and immune diseases with high unmet need.
Visit Apogee Therapeutics
Access participated in Spyre's PIPE financing announced in December 2023.
Spyre is developing next generation therapeutics for inflammatory bowel disease.
Visit Spyre Therapeutics
Access participated in Santa Ana Bio’s Series B financing announced in June 2024.
Santa Ana Bio is developing a pipeline of innovative biologic therapies to treat autoimmune and inflammatory disorders.
Visit Santa Ana Bio
Access co-led GRO’s Series B financing in July 2024.
GRO leverages synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics.
Visit GRO Biosciences
Access participated in Oruka’s financing announced in April 2024.
Oruka Therapeutics is developing novel biologics for the treatment of chronic skin diseases.
Visit Oruka Therapeutics
The RNAi process uses carefully selected RNA molecules to destroy the messenger RNAs (mRNAs) of harmful genes.
Dicerna Pharmaceuticals has developed a proprietary therapeutic platform based on RNA interference (RNAi) technology to silence specific genes known to cause or drive a wide range of diseases.
Visit Dicerna Pharmaceuticals
Access participated in Verona’s $200M private placement in July 2020.
Verona is developing a novel inhaled therapy for serious respiratory diseases.
Visit Verona Pharma
Access participated in DTx’s $100M Series B financing in February 2021. The company was acquired by Novartis in July 2023 for up to $1 billion.
DTx is using their proprietary fatty-acid based oligonucleotide delivery technology to develop novel therapies for genetic diseases.
Visit DTX Pharma
Lilly agreed to acquire DICE in June 2023 for $2.4 billion.
DICE is discovering and developing novel oral medicines for autoimmune diseases.
Visit DICE Therapeutics
Arvinas is a clinical-stage biotechnology company developing targeted protein degradation therapeutics.
Arvinas is engineering proteolysis targeting chimeras, or PROTAC® protein degraders, designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
Visit Arvinas
Access co-incubated Mariana, and invested in its Series A financing announced in December 2021. The company was acquired by Novartis in May 2024 for up to $1.75 billion.
Mariana Oncology is developing targeted radiopharmaceuticals for the treatment of high unmet need solid tumors.
Visit Mariana Oncology Access participated in Disc Medicine’s $50 million Series A in September 2019.
Disc Medicine is developing novel treatments for dysregulated iron metabolism.
Visit Disc Medicine Climb Bio
Climb Bio is developing budoprutug, an anti-CD19 antibody designed for a broad range of B-cell mediated diseases.
Visit Climb Bio The company was acquired by Sanofi for $3.7B in September 2020.
Principia was focused on developing novel therapies for immune mediated diseases.
Visit Principia Biopharma Access participated in the Series A financing of Day One announced in May 2020.
Day One develops therapies for people with cancer of all ages.
Visit Day One Biopharmaceuticals Access led Perfuse’s Series A financing in July 2020.
Perfuse is pursuing a novel mechanism to improve retinal perfusion for the treatment of multiple eye diseases.
Visit Perfuse Therapeutics Access participated in Nimbus’ $105M private financing announced in July 2021.
Nimbus harnesses cutting-edge technologies to design exquisitely selective small molecule therapeutics.
Visit Nimbus Therapeutics Access participated in Recludix’s $60M Series A announced in November 2021.
Recludix is discovering and developing potent and selective inhibitors for challenging protein targets in cancer and inflammatory diseases.
Visit Recludix Pharma Access led Halda’s Series B financing in December 2021.
Halda is discovering and developing novel small molecule drugs for cancer.
Visit Halda Therapeutics Access co-led Pandion’s $80M Series B financing in March 2020. The company was acquired by Merck for $1.85 billion in April 2021.
Pandion is developing biologic therapies for serious autoimmune disorders.
Visit Pandion Therapeutics Access participated in Upstream’s $200M Series A financing announced in June 2022.
Upstream is developing novel therapies for inflammatory and allergic diseases.
Visit Upstream Bio Access participated in the company’s $350 million Series A financing announced in July 2022.
Areteia is developing an oral drug for eosinophilic (allergic) asthma.
Visit Areteia Therapeutics Access led the company’s $300M Series C financing in September 2022.
Acelyrin is focused on identifying, acquiring, and developing transformative new therapies for conditions with high unmet need in autoimmunity and other disease areas.
Visit Acelyrin Access co-incubated the company, and co-led the Seed financing announced in October 2022.
Matchpoint is discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
Visit Matchpoint Therapeutics Access led Hemab’s Series B in February 2023.
Hemab is developing therapies for serious inherited bleeding disorders.
Visit Hemab Therapeutics Access participated in Zura’s $80M private placement announced in April 2023.
Zura is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
Visit Zura Bio Access led Vyne’s $88M private placement in October 2023.
Vyne is developing novel therapies for vitiligo and other autoimmune and inflammatory disorders.
Visit Vyne Therapeutics Apogee Therapeutics
Apogee Therapeutics is developing novel biologic therapies for inflammatory and immune diseases with high unmet need.
Visit Apogee Therapeutics Access participated in Spyre's PIPE financing announced in December 2023.
Spyre is developing next generation therapeutics for inflammatory bowel disease.
Visit Spyre Therapeutics Access participated in Santa Ana Bio’s Series B financing announced in June 2024.
Santa Ana Bio is developing a pipeline of innovative biologic therapies to treat autoimmune and inflammatory disorders.
Visit Santa Ana Bio Access co-led GRO’s Series B financing in July 2024.
GRO leverages synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics.
Visit GRO Biosciences Access participated in Oruka’s financing announced in April 2024.
Oruka Therapeutics is developing novel biologics for the treatment of chronic skin diseases.
Visit Oruka Therapeutics The RNAi process uses carefully selected RNA molecules to destroy the messenger RNAs (mRNAs) of harmful genes.
Dicerna Pharmaceuticals has developed a proprietary therapeutic platform based on RNA interference (RNAi) technology to silence specific genes known to cause or drive a wide range of diseases.
Visit Dicerna Pharmaceuticals Access participated in Verona’s $200M private placement in July 2020.
Verona is developing a novel inhaled therapy for serious respiratory diseases.
Visit Verona Pharma Access participated in DTx’s $100M Series B financing in February 2021. The company was acquired by Novartis in July 2023 for up to $1 billion.
DTx is using their proprietary fatty-acid based oligonucleotide delivery technology to develop novel therapies for genetic diseases.
Visit DTX Pharma Lilly agreed to acquire DICE in June 2023 for $2.4 billion.
DICE is discovering and developing novel oral medicines for autoimmune diseases.
Visit DICE Therapeutics Arvinas is a clinical-stage biotechnology company developing targeted protein degradation therapeutics.
Arvinas is engineering proteolysis targeting chimeras, or PROTAC® protein degraders, designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
Visit Arvinas Access co-incubated Mariana, and invested in its Series A financing announced in December 2021. The company was acquired by Novartis in May 2024 for up to $1.75 billion.
Mariana Oncology is developing targeted radiopharmaceuticals for the treatment of high unmet need solid tumors.
Visit Mariana Oncology